Paragon Sports Medicine

CJC-1295

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) consisting of a 29-amino-acid GHRH backbone, a modified GRF(1-29) analogue, with modifications designed to improve stability and prolong biological activity. Originally developed as a long-acting alternative to native GHRH, CJC-1295 incorporates amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, extending its half-life from minutes to days.

Researchers have studied whether it may stimulate sustained endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Its pharmacokinetic profile may allow less frequent dosing than other growth hormone secretagogues. Human outcome data remain limited, and CJC-1295 is not FDA approved.

Chemical structure diagram of Ipamorelin with labeled atoms and bonds.
Woman golfer finishing a golf swing on a green course with a large clubhouse and trees in the background.

Overview

CJC-1295 is reported to have greater stability than native GHRH because its amino acid modifications remove DPP-4 cleavage sites while preserving GHRH receptor binding affinity. The peptide exists in two forms: CJC-1295 with Drug Affinity Complex (DAC), which has an extended half-life, and CJC-1295 without DAC, which may produce more physiological pulsatile release patterns. The compound is metabolized primarily through peptidase enzymes and eliminated via renal excretion.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Chemical structure & Properties

  • Molecular Formula: C165H269N47O46
  • Molecular Weight: 3,647.28 Da
  • Sequence: Modified GRF(1-29) with Lys substitution and maleimido-propionyl-Lys attachment
  • Half-life: 6-8 days (with DAC), 30 minutes (without DAC)
  • Stability: Enhanced resistance to DPP-4 degradation through amino acid modifications

Mechanism of Action

CJC-1295 exerts its therapeutic effects through multiple interconnected molecular pathways:

Growth Hormone-Releasing Hormone Receptor Activation

CJC-1295 may selectively bind to and activate GHRH receptors on anterior pituitary somatotrophs, which may lead to:

  • Possible enhanced adenylyl cyclase activation and cyclic AMP production
  • Possible increased protein kinase A (PKA) phosphorylation cascades
  • Possible stimulation of growth hormone gene transcription and protein synthesis
  • Pulsatile growth hormone release mimicking natural physiological patterns

Growth Hormone and IGF-1 Axis Stimulation

The peptide may promote sustained hormone elevation through:

  • Possible stimulation of pituitary growth hormone secretion
  • Secondary hepatic insulin-like growth factor-1 (IGF-1) production
  • Possible activation of IGF-1 receptor signaling in peripheral tissues
  • Possible enhanced growth hormone binding protein (GHBP) interactions

Metabolic Pathway Modulation

CJC-1295 may influence cellular metabolism and energy utilization by:

  • May promote lipolysis through hormone-sensitive lipase activation
  • May enhance protein synthesis via mTOR and PI3K/Akt pathways
  • May improve insulin sensitivity and glucose uptake in muscle tissue
  • Facilitating fat oxidation and preferential fuel utilization

Tissue Regeneration and Repair

The peptide has been reported to show regenerative properties through:

  • Possible stimulation of satellite cell activation and muscle fiber regeneration
  • Possible enhanced collagen synthesis and connective tissue repair
  • Possible promotion of osteoblast activity and bone matrix formation
  • Possible acceleration of wound healing and tissue remodeling processes

Safety Profile and Considerations

Regulatory Status and Legal Considerations

Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.

FDA Status

  • Classification: Investigational peptide - not approved for therapeutic use
  • Approval Status: No FDA approval for human clinical applications
  • Research Use: Limited to approved clinical trials and research protocols
  • Regulatory Position:CJC-1295 is not on the FDA's active Category 2 list. It appears in the nominated-but-withdrawn section of the FDA's bulk drug substances page, meaning the nomination was withdrawn rather than acted on. Withdrawal does not authorize compounding: CJC-1295 is not on the FDA's 503A bulk drug substances list, so no lawful compounding pathway currently exists. It is not approved for therapeutic use.

WADA Status

  • Classification: Prohibited under S2: Peptide Hormones, Growth Factors
  • Athletic Use: Banned in competitive sports and athletic competitions
  • Testing: Detectable through specialized anti-doping analysis methods
  • Enforcement: Subject to sporting sanctions and competition disqualification

Legal Availability

  • Commercial Status: Not legally available as prescription medication
  • Market Presence: Available through research chemical suppliers and compounding pharmacies
  • Quality Control: Limited regulatory oversight for purity, potency, and authenticity
  • Clinical Use: Restricted to research institutions and experimental protocols
Man seated indoors with a soccer ball in natural light, representing Paragon’s musculoskeletal recovery expertise and regenerative treatment focus.

Conclusion

What the evidence supports

CJC-1295 is a long-acting growth-hormone-releasing hormone analog that has been studied in small, short-term human trials reporting sustained increases in growth hormone and IGF-1 levels. Outcome data is limited to those small studies, dosing has not been standardized, and there is no long-term safety data. CJC-1295 is not FDA approved for any therapeutic use and is not on the FDA's 503A bulk drug substances list, so no lawful compounding pathway currently exists; it is also prohibited under WADA. This page summarizes the published research and nothing further.

CJC-1295 SCIENTIFIC

DATA SUMMARY

Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
3,647.28 Da
29-amino-acid GRF(1-29) analogue
6-8 days (with DAC), 30 min (without DAC)
High subcutaneous, negligible oral
Up to several weeks (depending on form)
Application
GH Stimulation
Body Composition
IGF-1 Elevation
Metabolic Effects
Reported outcome (model)
GH raised 2-10x for 6+ days; IGF-1 raised 1.5-3x for 9-11 days
Reported: increased lean mass, reduced adiposity
Reported: increased serum IGF-1 levels
Reported: enhanced osteoblast activity, BMD increase
Study Type
Phase I Efficacy (Teichman)
GHRH-KO Mouse Study
Protein Profile Study
Population
24 healthy adults
GH-deficient mice
Normal adult subjects
Results
Reported: GH increased from 3 to 20 ng/mL
Complete growth normalization
Reported: GH/IGF-1 axis activation
Limitations
Short-term, small sample
Animal model, not human
Biochemical endpoints only
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
A mid-stage trial was halted after a participant death (not conclusively drug-linked); serious events cannot be excluded.
No significant organ-specific toxicity reported
Injection site reactions, mild fluid retention
Limited data beyond 6-month treatment periods
Authority
FDA
WADA
DEA
Classification
Investigational Peptide
S2 Peptide Hormones
Unscheduled
Status
Not approved for human use
Prohibited in sports
Not controlled substance

About this library

This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.

This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. CJC-1295 is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.

Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.